Immuron (ASX:IMC) has announced the continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.
Chief commercial officer Flavio Palumbo said, "As anticipated, we are achieving strong growth in North America with continued growth in Australia. We have secured core ranging in another nine pharmacy banner groups in Australia. We had our strongest monthly sales on amazon.com in the US. We now have distribution in ten pharmacy/grocery retailers in Canada."
Australian sales of Travelan grew 3 per cent in the three months to September to A$1.007 million. For the same period, US sales rose 48 per cent to A$0.456 million.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
